Indolent Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Indolent Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]
This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers includin…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Studying TAK-243 in Patients With Advanced Cancer [Phase 1]
This entry describes a Phase 1 clinical trial evaluating TAK-243 in adults with advanced cancers, including non-Hodgkin lymphoma and various…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients [NA]
This study examines how structured exercise affects immune phenotype in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic …
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating CD19 t-haNK and NAI with Rituximab in relapsed indolent non-Hodgkin lymphoma; the study is not yet recru…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]
Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating glofitamab and obinutuzumab in indolent non-Hodgkin lymphomas, including follicular lymphoma and marginal …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Lisaftoclax (APG-2575) as a monotherapy in indolent lymphomas, including Waldenström mac…
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating pomalidomide in combination with obinutuzumab for relapsed/refractory indolent non-Hodgkin lymphoma; the…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas [Phase 2]
A Phase 2 clinical trial evaluating the combination of acalabrutinib and obinutuzumab as initial therapy for previously untreated follicular…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Ongoing Phase 2 trial evaluating nivolumab in combination with DA-REPOCH chemotherapy for aggressive B-cell non-Hodgkin lymphomas, including…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma [Phase 1]
An early-phase study evaluating the combination of parsaclisib with standard therapy in newly diagnosed, high-risk diffuse large B-cell lymp…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]
Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating ultra-low-dose orbital radiation therapy for Stage I-IV indolent B-cell non-Hodgkin lymphoma and mantle cell lympho…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 trial is evaluating the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed indolent …
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 clinical trial of Axicabtagene Ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (follicular and marginal zone lymphom…
-
CLINICAL_TRIALS withdrawal · 2025-12-18Clinical Trial Update: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies [Phase 1]
A Phase 1 study of CNTY-101 in CD19-positive B-cell malignancies has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study of lenalidomide plus rituximab in previously untreated indolent non-Hodgkin lymphoma was terminated; results have been poste…
-
CLINICAL_TRIALS withdrawal · 2025-09-17Clinical Trial Update: Testing the Safety of CB-5339 in Patients With Cancer [Phase 1]
The Phase 1 clinical trial of CB-5339 in cancer patients has been withdrawn, with no study results reported.
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment [Phase 1]
Early-phase trial evaluating a three-drug combination (venetoclax, lenalidomide, and rituximab with hyaluronidase) in relapsed or refractory…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]
Phase 2 trial evaluating ME-401 in relapsed or refractory indolent non-Hodgkin lymphoma; the study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Indolent Non Follicular Lymphomas Prognostic Project
The clinical trial NCT02904577 focusing on prognostic factors for indolent non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Combating Cancer-Related Fatigue: A Personalized Supportive Care Program [NA]
This clinical trial update reports a UNC Lineberger Comprehensive Cancer Center study recruiting participants for a personalized supportive …